A small study of patients undergoing bariatric surgery suggests that weekly warfarin doses can change by as much as 20% postoperatively.
Anna D. Garrett, PharmD, BCPS
Advertisement
Anna D. Garrett is a clinical pharmacist and president of Dr. Anna Garrett (www.drannagarrett.com). Her mission is to help women in midlife maximize their mojo! Contact her at [email protected].
Articles by Anna D. Garrett, PharmD, BCPS
Ticagrelor is shown to be better at platelet inhibition. Warfarin seen as beneficial to patients with PAH. Dabigatran's problems aren't over.
Fondaparinux shown to be safe for patients with renal impairment.
FDA says no to rivaroxaban for ACS. ACCP updates DVT evidence. Fatal bleeds from dabigatran have tapered off
The debate on CHADS2 scoring vs. CHA2DS2-VASc continues
Advertisement
Latest Updated Articles
- Bariatric surgery affects postoperative warfarin dosing
November 12th 2013
- Fondaparinux safe in renal impairment
August 10th 2012
- Ticagrelor tops prasugrel in pharmacodynamic study
September 15th 2012
- Panel says no to rivaroxaban for ACS
July 15th 2012
- CHADS2 scoring debate continues
June 15th 2012
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Q&A: Pharmacists Can Address ADA Standards Across All Settings
5